What It Is
Tirzepatide is a synthetic peptide medication that acts as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.[1] Incretins are gut-derived signals that help coordinate insulin release, appetite, and glucose handling after meals, and tirzepatide's engineered structure allows once-weekly subcutaneous dosing.
In the United States, tirzepatide is sold under two FDA-approved brand names with distinct indications: Mounjaro for improving glycemic control in adults with type 2 diabetes, and Zepbound for chronic weight management in adults with obesity or overweight plus a weight-related condition, as well as for moderate-to-severe obstructive sleep apnea in adults with obesity.[2] These are genuine drug approvals with full prescribing labels, not general "research peptide" status.
How It Works
By activating the GLP-1 receptor, tirzepatide increases glucose-dependent insulin secretion, reduces glucagon release, slows gastric emptying, and affects appetite signaling in the brain.[3] Its added activity at the GIP receptor is thought to contribute complementary metabolic effects, though its exact individual contribution to clinical outcomes remains an active research question.
Because insulin secretion is glucose-dependent, hypoglycemia risk on its own is relatively low, but rises meaningfully when combined with insulin or sulfonylureas. Delayed gastric emptying is also clinically relevant beyond appetite: it can reduce absorption of oral medications, including oral contraceptives.
What the Research Shows
The SURPASS trial program evaluated tirzepatide in type 2 diabetes; in SURPASS-2, it produced larger A1C and weight reductions than semaglutide 1 mg over 40 weeks, with gastrointestinal effects common in both groups.[4] Other SURPASS trials compared it against insulin-based regimens, generally supporting glycemic benefits in the populations studied.
For weight management, SURMOUNT-1 reported substantial dose-related weight reductions over 72 weeks in adults with obesity or overweight without diabetes, and SURMOUNT-2 extended this to people with obesity and type 2 diabetes.[5] A separate trial supporting the sleep apnea indication measured reduced apnea-hypopnea index in people with obesity. A withdrawal study (SURMOUNT-4) found people who stopped tirzepatide after initial treatment regained weight, underscoring these are treatment effects requiring continued use, not a one-time fix. Claims about anti-aging or performance enhancement are not supported by this trial base.
Safety & Side Effects
The most common adverse effects across trials and labeling are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, often more pronounced during dose escalation.[1] Labels also carry more serious warnings that require clinical attention.
- Boxed warning for thyroid C-cell tumors seen in rodent studies, with unknown relevance to humans; contraindicated in personal or family history of medullary thyroid carcinoma or MEN2
- Pancreatitis and gallbladder disease, including cholelithiasis and cholecystitis
- Acute kidney injury, generally linked to dehydration from severe GI symptoms
- Hypoglycemia risk when combined with insulin or sulfonylureas
- Hypersensitivity reactions, including anaphylaxis and angioedema
- Reduced absorption of oral contraceptives after initiation and dose escalation, and aspiration risk during anesthesia due to delayed gastric emptying
Regulatory Status
Tirzepatide is FDA-approved, but the approval is product- and indication-specific: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management and, separately, obstructive sleep apnea in adults with obesity.[2] These approvals cover manufacturing quality, labeling, dosing, and monitored safety data for those exact indications, not tirzepatide as a general concept.
Compounded tirzepatide, often sold as a cheaper alternative outside standard pharmacy channels, is a separate, unapproved category. The FDA has warned that unapproved GLP-1 drug products marketed for weight loss can pose risks including dosing errors and quality problems, since they have not undergone premarket review for safety, effectiveness, or quality.[6] Compounded versions should not be assumed equivalent to the approved, trial-tested product.
How Tirzepatide Differs From Semaglutide
Tirzepatide is often compared with semaglutide (Ozempic, Wegovy), a GLP-1-only receptor agonist. In the head-to-head SURPASS-2 trial, tirzepatide produced greater A1C and body weight reductions than semaglutide 1 mg in people with type 2 diabetes, but that single comparison does not cover every semaglutide dose, product, or population.[4]
The dual-receptor mechanism is a meaningful pharmacological difference, but it does not automatically mean tirzepatide is the better choice for every individual — tolerability, contraindications, cost, access, and personal medical history all factor into that decision, which should be made with a clinician rather than inferred from trial averages alone.